Skip to main content
Fig. 3 | Journal of Neuroinflammation

Fig. 3

From: Targeting S100A4 with niclosamide attenuates inflammatory and profibrotic pathways in models of amyotrophic lateral sclerosis

Fig. 3

S100A4 is involved in profibrotic pathways. Fibroblasts from ALS patients with no known ALS variants (uvALS) and C9orf72 ALS patients were transfected with S100A4 siRNA and scrambled siRNA (Scr). Cells were lysed after 72 h of transfection. a Protein lysates of uvALS fibroblasts were assayed by Western blot with anti-STAT3, anti-α-SMA, anti-N-cadherin. The levels of GAPDH expression were used as loading control. Values are mean ± SEM, n = 3 individuals, experiments repeated in triplicate; two-tailed t test. t value: 3.687, degrees of freedom: 4 (STAT3); t value: 3.169, degrees of freedom: 4 (α-SMA); t value: 3.474, degrees of freedom: 4 (N-cadherin). b Protein lysates of C9orf72 ALS fibroblasts were assayed by Western blot with anti-STAT3, anti-α-SMA, anti-N-cadherin. The levels of GAPDH expression were used as loading control. Values are mean ± SEM, n = 3 individuals, experiments repeated in triplicate; two-tailed t test. t value: 5.066, degrees of freedom: 4 (STAT3); t value: 2.812, degrees of freedom: 4 (α-SMA); t value: 4.940, degrees of freedom: 4 (N-cadherin). *p < 0.05 and **p < 0.01 vs. scrambled siRNA

Back to article page